Q1 Earnings Estimate for NRIX Issued By Leerink Partnrs

Nurix Therapeutics, Inc. (NASDAQ:NRIX) – Equities researchers at Leerink Partnrs issued their Q1 2025 earnings per share estimates for shares of Nurix Therapeutics in a research note issued to investors on Monday, March 17th. Leerink Partnrs analyst F. Khurshid forecasts that the company will post earnings per share of ($0.89) for the quarter. Leerink Partnrs currently has a “Hold” rating on the stock. The consensus estimate for Nurix Therapeutics’ current full-year earnings is ($2.99) per share. Leerink Partnrs also issued estimates for Nurix Therapeutics’ Q2 2025 earnings at ($0.93) EPS.

Several other research firms also recently weighed in on NRIX. Stifel Nicolaus raised their price objective on Nurix Therapeutics from $34.00 to $36.00 and gave the company a “buy” rating in a report on Wednesday, January 29th. Leerink Partners started coverage on Nurix Therapeutics in a report on Monday. They set a “market perform” rating and a $16.00 price objective on the stock. Needham & Company LLC cut their price objective on Nurix Therapeutics from $29.00 to $28.00 and set a “buy” rating on the stock in a report on Wednesday, January 29th. BTIG Research started coverage on Nurix Therapeutics in a report on Tuesday, December 10th. They set a “buy” rating and a $35.00 price objective on the stock. Finally, Stephens reaffirmed an “overweight” rating and set a $31.00 target price on shares of Nurix Therapeutics in a research report on Tuesday, January 21st. Three equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $30.88.

Nurix Therapeutics Stock Down 0.2 %

NASDAQ NRIX opened at $13.87 on Wednesday. Nurix Therapeutics has a twelve month low of $11.90 and a twelve month high of $29.56. The company has a market cap of $1.05 billion, a price-to-earnings ratio of -4.80 and a beta of 2.18. The business’s fifty day moving average is $17.10 and its 200 day moving average is $20.88.

Nurix Therapeutics (NASDAQ:NRIX) last issued its earnings results on Tuesday, January 28th. The company reported ($0.75) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.08). Nurix Therapeutics had a negative net margin of 354.85% and a negative return on equity of 53.65%.

Insider Transactions at Nurix Therapeutics

In related news, CFO Houte Hans Van sold 2,811 shares of the business’s stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $19.85, for a total value of $55,798.35. Following the completion of the sale, the chief financial officer now directly owns 39,549 shares of the company’s stock, valued at $785,047.65. The trade was a 6.64 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Gwenn Hansen sold 3,690 shares of the business’s stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $19.85, for a total value of $73,246.50. Following the completion of the sale, the insider now directly owns 55,937 shares of the company’s stock, valued at $1,110,349.45. The trade was a 6.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 12,326 shares of company stock valued at $213,449. Corporate insiders own 7.20% of the company’s stock.

Institutional Trading of Nurix Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Amalgamated Bank increased its position in Nurix Therapeutics by 30.6% in the 3rd quarter. Amalgamated Bank now owns 2,182 shares of the company’s stock valued at $49,000 after buying an additional 511 shares in the last quarter. The Manufacturers Life Insurance Company boosted its stake in Nurix Therapeutics by 2.1% during the 4th quarter. The Manufacturers Life Insurance Company now owns 31,025 shares of the company’s stock valued at $585,000 after purchasing an additional 642 shares during the last quarter. Corebridge Financial Inc. boosted its stake in Nurix Therapeutics by 2.3% during the 4th quarter. Corebridge Financial Inc. now owns 34,907 shares of the company’s stock valued at $658,000 after purchasing an additional 770 shares during the last quarter. Kennedy Capital Management LLC boosted its stake in Nurix Therapeutics by 0.7% during the 4th quarter. Kennedy Capital Management LLC now owns 114,623 shares of the company’s stock valued at $2,159,000 after purchasing an additional 785 shares during the last quarter. Finally, US Bancorp DE boosted its stake in Nurix Therapeutics by 144.7% during the 4th quarter. US Bancorp DE now owns 1,424 shares of the company’s stock valued at $27,000 after purchasing an additional 842 shares during the last quarter.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.